Methylprednisolone hemisuccinate
- Generic Name
- Methylprednisolone hemisuccinate
- Brand Names
- Solu-medrol
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34O8
- CAS Number
- 2921-57-5
- Unique Ingredient Identifier
- 5GMR90S4KN
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Associated Conditions
- Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04263402
- Locations
- 🇨🇳
Department and Institute of Infectious Disease, Wuhan, Hubei, China
Stem Cell Transplantation in Crohn's Disease
- Conditions
- Interventions
- Drug: MesnaDrug: CyclophosphamideDrug: FilgrastimProcedure: Apheresis catheter placementProcedure: LeukapheresisDrug: FludarabineDrug: MethylprednisoloneDrug: DiphenhydramineDrug: AcetaminophenDrug: anti-thymocyte globulin (rabbit)Drug: lymphocyte immune globulinBiological: Peripheral Blood Stem Cell InfusionDrug: Cytoxan
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT04224558
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 271
- Registration Number
- NCT04221477
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇩🇪Universitaetsmedizin Johannes Gutenberg; Rheumatologie, Mainz, Germany
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04220632
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
- Conditions
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04216524
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
The Effect of PAP on ISSHL Comorbided With OSA
- Conditions
- Interventions
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Target Recruit Count
- 102
- Registration Number
- NCT04192656
- Locations
- 🇨🇳
Beijing Tsinhgua Changgung Hospital, Beijing, Beijing, China
Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU
- Conditions
- Interventions
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Versailles Hospital
- Target Recruit Count
- 440
- Registration Number
- NCT04163536
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷CHU Louis Mourier, Colombes, France
🇫🇷CHRU lille, Lille, France
Evaluation of Methylprednisolone or Ibuprofen on Efficacy of Nerve Blocks With Symptomatic Irreversible Pulpitis
- Conditions
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- Walter Reed National Military Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT04157036
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT04151082
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Prevail Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04127578
- Locations
- 🇺🇸
Rocky Mountain Clinical Research - CenExel - PPDS, 701 East Hampden Avenue Suite 510, Englewood, Colorado, United States
🇺🇸Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States
🇮🇱Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.